$DXCM Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in DEXCOM INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in DEXCOM INC. Get notifications about new insider transactions in DEXCOM INC for free.
Page: < prev 1 ... 5 6 7 8 9 10 11 12 13 ... 27 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Sep 13 2017 | DXCM | DEXCOM INC | Balo Andrew K | EVP, Reg. Strategy, ... | Sell | D | 71.81 | 4,184 | 300,467 | 92,629 | 96.8 K to 92.6 K (-4.32 %) |
Sep 13 2017 | DXCM | DEXCOM INC | Balo Andrew K | EVP, Reg. Strategy, ... | Sell | S | 72.27 | 3,244 | 234,441 | 96,813 | 100.1 K to 96.8 K (-3.24 %) |
Sep 13 2017 | DXCM | DEXCOM INC | DOUBLEDAY RICHARD | EVP, Chief Commerci ... | Sell | D | 71.81 | 4,184 | 300,467 | 65,049 | 69.2 K to 65 K (-6.04 %) |
Sep 13 2017 | DXCM | DEXCOM INC | DOUBLEDAY RICHARD | EVP, Chief Commerci ... | Sell | D | 71.81 | 3,347 | 240,359 | 69,233 | 72.6 K to 69.2 K (-4.61 %) |
Sep 08 2017 | DXCM | DEXCOM INC | Blackford Quentin S. | EVP, CFO, PFO & PAO | Grant | A | 0.00 | 62,358 | 62 | 63,756 | 1.4 K to 63.8 K (+4,460.52 %) |
Aug 24 2017 | DXCM | DEXCOM INC | Pacelli Steven Robert | EVP, Strategy & Cor ... | Sell | S | 75.26 | 3,987 | 300,045 | 108,087 | 112.1 K to 108.1 K (-3.56 %) |
Aug 24 2017 | DXCM | DEXCOM INC | DOUBLEDAY RICHARD | EVP, Chief Commerci ... | Sell | S | 75.26 | 1,635 | 123,053 | 23,785 | 25.4 K to 23.8 K (-6.43 %) |
Aug 24 2017 | DXCM | DEXCOM INC | ACE HEATHER S | SVP Human Resources | Sell | D | 75.33 | 2,617 | 197,145 | 46,766 | 49.4 K to 46.8 K (-5.30 %) |
Aug 15 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Sell | S | 69.77 | 6,000 | 418,637 | 320,680 | 326.7 K to 320.7 K (-1.84 %) |
Aug 11 2017 | DXCM | DEXCOM INC | Balo Andrew K | EVP, Reg. Strategy, ... | Sell | S | 71.18 | 3,244 | 230,921 | 99,989 | 103.2 K to 100 K (-3.14 %) |
Jul 25 2017 | DXCM | DEXCOM INC | Pacelli Steven Robert | EVP, Strategy & Cor ... | Sell | S | 69.47 | 1,450 | 100,725 | 112,074 | 113.5 K to 112.1 K (-1.28 %) |
Jul 12 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Sell | S | 71.86 | 6,000 | 431,174 | 326,680 | 332.7 K to 326.7 K (-1.80 %) |
Jul 12 2017 | DXCM | DEXCOM INC | Balo Andrew K | EVP, Reg. Strategy, ... | Sell | S | 71.55 | 3,200 | 228,972 | 103,233 | 106.4 K to 103.2 K (-3.01 %) |
Jun 27 2017 | DXCM | DEXCOM INC | DOUBLEDAY RICHARD | EVP, Chief Commerci ... | Sell | S | 78.22 | 3,187 | 249,273 | 25,420 | 28.6 K to 25.4 K (-11.14 %) |
Jun 27 2017 | DXCM | DEXCOM INC | Pacelli Steven Robert | EVP, Strategy & Cor ... | Sell | S | 78.19 | 1,450 | 113,378 | 113,524 | 115 K to 113.5 K (-1.26 %) |
Jun 13 2017 | DXCM | DEXCOM INC | Balo Andrew K | EVP, Clinical and R ... | Sell | S | 69.06 | 3,200 | 220,989 | 106,433 | 109.6 K to 106.4 K (-2.92 %) |
Jun 13 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Sell | S | 69.07 | 6,000 | 414,411 | 332,680 | 338.7 K to 332.7 K (-1.77 %) |
Jun 05 2017 | DXCM | DEXCOM INC | SKYLER JAY S | Director | Grant | A | 0.00 | 4,553 | 5 | 4,553 | 0 to 4.6 K |
Jun 05 2017 | DXCM | DEXCOM INC | KAHN BARBARA | Director | Grant | A | 0.00 | 4,353 | 4 | 4,353 | 0 to 4.4 K |
Jun 05 2017 | DXCM | DEXCOM INC | AUGUSTINOS NICHOLAS | Director | Grant | A | 0.00 | 4,353 | 4 | 31,015 | 26.7 K to 31 K (+16.33 %) |
Jun 05 2017 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Grant | A | 0.00 | 4,952 | 5 | 20,595 | 15.6 K to 20.6 K (+31.66 %) |
Jun 05 2017 | DXCM | DEXCOM INC | Collins Richard Alexander | Director | Grant | A | 0.00 | 4,353 | 4 | 5,855 | 1.5 K to 5.9 K (+289.81 %) |
Jun 05 2017 | DXCM | DEXCOM INC | Collins Richard Alexander | Director | Grant | A | 0.00 | 1,002 | 1 | 1,502 | 500 to 1.5 K (+200.40 %) |
Jun 05 2017 | DXCM | DEXCOM INC | ALTMAN STEVEN R | Director | Grant | A | 0.00 | 4,353 | 4 | 4,353 | 0 to 4.4 K |
Jun 05 2017 | DXCM | DEXCOM INC | TOPOL ERIC | Director | Grant | A | 0.00 | 4,653 | 5 | 4,653 | 0 to 4.7 K |
Jun 05 2017 | DXCM | DEXCOM INC | Abbey Donald | EVP Quality | Sell | D | 66.38 | 7,784 | 516,707 | 74,726 | 82.5 K to 74.7 K (-9.43 %) |
May 26 2017 | DXCM | DEXCOM INC | GREGG TERRANCE H | Executive Chairman | Option Exercise | M | 6.85 | 30,000 | 205,500 | 0 | |
May 26 2017 | DXCM | DEXCOM INC | GREGG TERRANCE H | Executive Chairman | Buy | M | 6.85 | 30,000 | 205,500 | 484,559 | 454.6 K to 484.6 K (+6.60 %) |
May 25 2017 | DXCM | DEXCOM INC | Pacelli Steven Robert | EVP, Strategy & Cor ... | Sell | S | 68.24 | 1,450 | 98,949 | 114,974 | 116.4 K to 115 K (-1.25 %) |
May 25 2017 | DXCM | DEXCOM INC | DOUBLEDAY RICHARD | EVP, Chief Commerci ... | Sell | S | 68.29 | 3,182 | 217,290 | 28,607 | 31.8 K to 28.6 K (-10.01 %) |
May 18 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Option Exercise | M | 8.79 | 3,649 | 32,075 | 0 | |
May 18 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Sell | S | 68.39 | 5,000 | 341,925 | 338,680 | 343.7 K to 338.7 K (-1.45 %) |
May 18 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Sell | S | 68.40 | 3,649 | 249,600 | 343,680 | 347.3 K to 343.7 K (-1.05 %) |
May 18 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Buy | M | 8.79 | 3,649 | 32,075 | 347,329 | 343.7 K to 347.3 K (+1.06 %) |
May 17 2017 | DXCM | DEXCOM INC | Pacelli Steven Robert | EVP, Strategy & Cor ... | Gift | G | 0.00 | 1,000 | 0 | 116,424 | 117.4 K to 116.4 K (-0.85 %) |
May 12 2017 | DXCM | DEXCOM INC | Balo Andrew K | EVP, Clinical and R ... | Sell | S | 71.93 | 3,200 | 230,176 | 109,633 | 112.8 K to 109.6 K (-2.84 %) |
Apr 26 2017 | DXCM | DEXCOM INC | Pacelli Steven Robert | EVP, Strategy & Cor ... | Sell | S | 75.89 | 1,450 | 110,041 | 117,424 | 118.9 K to 117.4 K (-1.22 %) |
Apr 26 2017 | DXCM | DEXCOM INC | DOUBLEDAY RICHARD | EVP, Chief Commerci ... | Sell | S | 75.78 | 3,182 | 241,131 | 6,369 | 9.6 K to 6.4 K (-33.32 %) |
Apr 24 2017 | DXCM | DEXCOM INC | GREGG TERRANCE H | Executive Chairman | Sell | S | 74.10 | 15,000 | 1,111,500 | 40,882 | 55.9 K to 40.9 K (-26.84 %) |
Apr 19 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Option Exercise | M | 8.79 | 10,000 | 87,900 | 3,649 | |
Apr 19 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Sell | S | 75.63 | 10,000 | 756,317 | 343,680 | 353.7 K to 343.7 K (-2.83 %) |
Apr 19 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Buy | M | 8.79 | 10,000 | 87,900 | 353,680 | 343.7 K to 353.7 K (+2.91 %) |
Apr 12 2017 | DXCM | DEXCOM INC | Balo Andrew K | EVP, Clinical and R ... | Sell | S | 78.19 | 3,200 | 250,208 | 112,833 | 116 K to 112.8 K (-2.76 %) |
Mar 24 2017 | DXCM | DEXCOM INC | Pacelli Steven Robert | EVP, Strategy & Cor ... | Sell | S | 76.25 | 3,987 | 304,006 | 118,874 | 122.9 K to 118.9 K (-3.25 %) |
Mar 24 2017 | DXCM | DEXCOM INC | DOUBLEDAY RICHARD | EVP, Chief Commerci ... | Sell | S | 76.38 | 3,182 | 243,029 | 9,551 | 12.7 K to 9.6 K (-24.99 %) |
Mar 24 2017 | DXCM | DEXCOM INC | ROPER JESS | SVP, CFO | Sell | S | 75.97 | 2,000 | 151,937 | 8,452 | 10.5 K to 8.5 K (-19.14 %) |
Mar 21 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Option Exercise | M | 8.79 | 10,000 | 87,900 | 13,649 | |
Mar 21 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Sell | S | 77.82 | 10,000 | 778,158 | 343,680 | 353.7 K to 343.7 K (-2.83 %) |
Mar 21 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Buy | M | 8.79 | 10,000 | 87,900 | 353,680 | 343.7 K to 353.7 K (+2.91 %) |
Mar 16 2017 | DXCM | DEXCOM INC | KAHN BARBARA | Director | Sell | S | 77.36 | 3,000 | 232,080 | 21,304 | 24.3 K to 21.3 K (-12.34 %) |
Mar 15 2017 | DXCM | DEXCOM INC | Leach Jacob Steven | SVP, Research & Dev ... | Option Exercise | M | 7.63 | 7,500 | 57,225 | 0 | |
Mar 15 2017 | DXCM | DEXCOM INC | Leach Jacob Steven | SVP, Research & Dev ... | Sell | S | 77.32 | 3,050 | 235,824 | 82,155 | 85.2 K to 82.2 K (-3.58 %) |
Mar 15 2017 | DXCM | DEXCOM INC | Leach Jacob Steven | SVP, Research & Dev ... | Sell | S | 77.78 | 2,732 | 212,485 | 85,205 | 87.9 K to 85.2 K (-3.11 %) |
Mar 15 2017 | DXCM | DEXCOM INC | Leach Jacob Steven | SVP, Research & Dev ... | Sell | S | 78.07 | 5,194 | 405,506 | 87,937 | 93.1 K to 87.9 K (-5.58 %) |
Mar 15 2017 | DXCM | DEXCOM INC | Leach Jacob Steven | SVP, Research & Dev ... | Buy | M | 7.63 | 7,500 | 57,225 | 93,131 | 85.6 K to 93.1 K (+8.76 %) |
Mar 15 2017 | DXCM | DEXCOM INC | Leach Jacob Steven | SVP, Research & Dev ... | Sell | D | 77.55 | 2,538 | 196,823 | 85,631 | 88.2 K to 85.6 K (-2.88 %) |
Mar 15 2017 | DXCM | DEXCOM INC | Leach Jacob Steven | SVP, Research & Dev ... | Sell | D | 77.55 | 5,473 | 424,434 | 88,169 | 93.6 K to 88.2 K (-5.84 %) |
Mar 15 2017 | DXCM | DEXCOM INC | Leach Jacob Steven | SVP, Research & Dev ... | Sell | D | 77.55 | 1,950 | 151,224 | 93,642 | 95.6 K to 93.6 K (-2.04 %) |
Mar 15 2017 | DXCM | DEXCOM INC | Leach Jacob Steven | SVP, Research & Dev ... | Sell | S | 77.24 | 3,012 | 232,650 | 95,592 | 98.6 K to 95.6 K (-3.05 %) |
Mar 15 2017 | DXCM | DEXCOM INC | Leach Jacob Steven | SVP, Research & Dev ... | Sell | S | 77.56 | 7,329 | 568,423 | 98,604 | 105.9 K to 98.6 K (-6.92 %) |
Mar 14 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Sell | S | 77.74 | 14,400 | 1,119,514 | 10,442 | 24.8 K to 10.4 K (-57.97 %) |
Mar 14 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Sell | D | 77.55 | 3,964 | 307,411 | 24,842 | 28.8 K to 24.8 K (-13.76 %) |
Mar 14 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Sell | D | 77.55 | 6,694 | 519,124 | 28,806 | 35.5 K to 28.8 K (-18.86 %) |
Mar 14 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Buy | J | 78.24 | 12,667 | 991,066 | 35,500 | 22.8 K to 35.5 K (+55.48 %) |
Mar 14 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Buy | J | 78.24 | 7,500 | 586,800 | 22,833 | 15.3 K to 22.8 K (+48.91 %) |
Mar 14 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Buy | J | 78.24 | 11,834 | 925,892 | 15,333 | 3.5 K to 15.3 K (+338.21 %) |
Mar 14 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Sell | D | 77.55 | 6,254 | 485,001 | 34,079 | 40.3 K to 34.1 K (-15.51 %) |
Mar 14 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Sell | J | 78.24 | 12,667 | 991,066 | 40,333 | 53 K to 40.3 K (-23.90 %) |
Mar 14 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Sell | J | 78.24 | 7,500 | 586,800 | 53,000 | 60.5 K to 53 K (-12.40 %) |
Mar 14 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Sell | J | 78.24 | 11,834 | 925,892 | 60,500 | 72.3 K to 60.5 K (-16.36 %) |
Mar 14 2017 | DXCM | DEXCOM INC | ROPER JESS | SVP, CFO | Sell | D | 77.55 | 5,120 | 397,059 | 46,497 | 51.6 K to 46.5 K (-9.92 %) |
Mar 14 2017 | DXCM | DEXCOM INC | ROPER JESS | SVP, CFO | Sell | D | 77.55 | 1,948 | 151,069 | 51,617 | 53.6 K to 51.6 K (-3.64 %) |
Mar 14 2017 | DXCM | DEXCOM INC | ROPER JESS | SVP, CFO | Sell | D | 77.55 | 2,538 | 196,823 | 53,565 | 56.1 K to 53.6 K (-4.52 %) |
Mar 14 2017 | DXCM | DEXCOM INC | MOY JEFFREY | SVP, Operations | Sell | D | 77.55 | 5,813 | 450,802 | 64,664 | 70.5 K to 64.7 K (-8.25 %) |
Mar 14 2017 | DXCM | DEXCOM INC | MOY JEFFREY | SVP, Operations | Sell | D | 77.55 | 2,867 | 222,338 | 70,477 | 73.3 K to 70.5 K (-3.91 %) |
Mar 14 2017 | DXCM | DEXCOM INC | MOY JEFFREY | SVP, Operations | Sell | D | 77.55 | 3,213 | 249,170 | 73,344 | 76.6 K to 73.3 K (-4.20 %) |
Mar 14 2017 | DXCM | DEXCOM INC | MOY JEFFREY | SVP, Operations | Buy | J | 78.24 | 11,000 | 860,640 | 76,557 | 65.6 K to 76.6 K (+16.78 %) |
Mar 14 2017 | DXCM | DEXCOM INC | MOY JEFFREY | SVP, Operations | Buy | J | 78.24 | 6,667 | 521,626 | 65,557 | 58.9 K to 65.6 K (+11.32 %) |
Mar 14 2017 | DXCM | DEXCOM INC | MOY JEFFREY | SVP, Operations | Buy | J | 78.24 | 8,334 | 652,052 | 58,890 | 50.6 K to 58.9 K (+16.48 %) |
Mar 14 2017 | DXCM | DEXCOM INC | MOY JEFFREY | SVP, Operations | Sell | J | 78.24 | 11,000 | 860,640 | 57,486 | 68.5 K to 57.5 K (-16.06 %) |
Mar 14 2017 | DXCM | DEXCOM INC | MOY JEFFREY | SVP, Operations | Sell | J | 78.24 | 6,667 | 521,626 | 68,486 | 75.2 K to 68.5 K (-8.87 %) |
Mar 14 2017 | DXCM | DEXCOM INC | MOY JEFFREY | SVP, Operations | Sell | J | 78.24 | 8,334 | 652,052 | 75,153 | 83.5 K to 75.2 K (-9.98 %) |
Mar 14 2017 | DXCM | DEXCOM INC | Balo Andrew K | EVP, Clinical and R ... | Sell | D | 77.55 | 3,208 | 248,782 | 116,033 | 119.2 K to 116 K (-2.69 %) |
Mar 14 2017 | DXCM | DEXCOM INC | Balo Andrew K | EVP, Clinical and R ... | Sell | D | 77.55 | 6,694 | 519,124 | 119,241 | 125.9 K to 119.2 K (-5.32 %) |
Mar 14 2017 | DXCM | DEXCOM INC | Balo Andrew K | EVP, Clinical and R ... | Sell | D | 77.55 | 3,528 | 273,599 | 125,935 | 129.5 K to 125.9 K (-2.73 %) |
Mar 14 2017 | DXCM | DEXCOM INC | Balo Andrew K | EVP, Clinical and R ... | Sell | S | 77.71 | 3,200 | 248,672 | 129,463 | 132.7 K to 129.5 K (-2.41 %) |
Mar 10 2017 | DXCM | DEXCOM INC | DOUBLEDAY RICHARD | EVP, Chief Commerci ... | Sell | D | 77.55 | 3,208 | 248,782 | 97,815 | 101 K to 97.8 K (-3.18 %) |
Mar 10 2017 | DXCM | DEXCOM INC | DOUBLEDAY RICHARD | EVP, Chief Commerci ... | Sell | D | 77.55 | 3,527 | 273,521 | 101,023 | 104.6 K to 101 K (-3.37 %) |
Mar 10 2017 | DXCM | DEXCOM INC | DOUBLEDAY RICHARD | EVP, Chief Commerci ... | Sell | D | 77.55 | 6,694 | 519,124 | 104,550 | 111.2 K to 104.6 K (-6.02 %) |
Mar 10 2017 | DXCM | DEXCOM INC | DOUBLEDAY RICHARD | EVP, Chief Commerci ... | Grant | A | 0.00 | 27,510 | 28 | 111,244 | 83.7 K to 111.2 K (+32.85 %) |
Mar 10 2017 | DXCM | DEXCOM INC | MOY JEFFREY | SVP, Operations | Grant | A | 0.00 | 21,883 | 22 | 83,487 | 61.6 K to 83.5 K (+35.52 %) |
Mar 10 2017 | DXCM | DEXCOM INC | Pacelli Steven Robert | EVP, Strategy & Cor ... | Sell | D | 77.55 | 6,694 | 519,124 | 122,861 | 129.6 K to 122.9 K (-5.17 %) |
Mar 10 2017 | DXCM | DEXCOM INC | Pacelli Steven Robert | EVP, Strategy & Cor ... | Sell | D | 77.55 | 4,540 | 352,080 | 129,555 | 134.1 K to 129.6 K (-3.39 %) |
Mar 10 2017 | DXCM | DEXCOM INC | Pacelli Steven Robert | EVP, Strategy & Cor ... | Sell | D | 77.55 | 3,824 | 296,553 | 134,095 | 137.9 K to 134.1 K (-2.77 %) |
Mar 10 2017 | DXCM | DEXCOM INC | Pacelli Steven Robert | EVP, Strategy & Cor ... | Grant | A | 0.00 | 27,510 | 28 | 137,919 | 110.4 K to 137.9 K (+24.92 %) |
Mar 10 2017 | DXCM | DEXCOM INC | LISTER JOHN | General Manager, EM ... | Option Exercise | M | 8.85 | 3,000 | 26,550 | 10,939 | |
Mar 10 2017 | DXCM | DEXCOM INC | LISTER JOHN | General Manager, EM ... | Sell | D | 77.55 | 3,537 | 274,296 | 84,034 | 87.6 K to 84 K (-4.04 %) |
Mar 10 2017 | DXCM | DEXCOM INC | LISTER JOHN | General Manager, EM ... | Sell | D | 77.55 | 6,161 | 477,789 | 87,571 | 93.7 K to 87.6 K (-6.57 %) |
Mar 10 2017 | DXCM | DEXCOM INC | LISTER JOHN | General Manager, EM ... | Sell | S | 77.67 | 3,000 | 233,002 | 93,732 | 96.7 K to 93.7 K (-3.10 %) |
Mar 10 2017 | DXCM | DEXCOM INC | LISTER JOHN | General Manager, EM ... | Buy | M | 8.85 | 3,000 | 26,550 | 96,732 | 93.7 K to 96.7 K (+3.20 %) |
Mar 10 2017 | DXCM | DEXCOM INC | LISTER JOHN | General Manager, EM ... | Grant | A | 0.00 | 23,134 | 23 | 93,732 | 70.6 K to 93.7 K (+32.77 %) |
Mar 10 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Sell | D | 77.55 | 7,927 | 614,744 | 343,680 | 351.6 K to 343.7 K (-2.25 %) |
Mar 10 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Sell | D | 77.55 | 15,853 | 1,229,410 | 351,607 | 367.5 K to 351.6 K (-4.31 %) |
Mar 10 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Sell | D | 77.55 | 13,211 | 1,024,521 | 367,460 | 380.7 K to 367.5 K (-3.47 %) |
Mar 10 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Grant | A | 0.00 | 81,280 | 81 | 380,671 | 299.4 K to 380.7 K (+27.15 %) |
Mar 10 2017 | DXCM | DEXCOM INC | GREGG TERRANCE H | Executive Chairman | Sell | D | 77.55 | 14,512 | 1,125,414 | 454,559 | 469.1 K to 454.6 K (-3.09 %) |
Mar 10 2017 | DXCM | DEXCOM INC | GREGG TERRANCE H | Executive Chairman | Sell | D | 77.55 | 1,661 | 128,812 | 469,071 | 470.7 K to 469.1 K (-0.35 %) |
Mar 10 2017 | DXCM | DEXCOM INC | GREGG TERRANCE H | Executive Chairman | Grant | A | 0.00 | 30,887 | 31 | 470,732 | 439.8 K to 470.7 K (+7.02 %) |
Mar 10 2017 | DXCM | DEXCOM INC | Balo Andrew K | EVP, Clinical and R ... | Grant | A | 0.00 | 28,761 | 29 | 132,663 | 103.9 K to 132.7 K (+27.68 %) |
Mar 10 2017 | DXCM | DEXCOM INC | Abbey Donald | EVP Quality | Grant | A | 0.00 | 27,510 | 28 | 82,510 | 55 K to 82.5 K (+50.02 %) |
Mar 10 2017 | DXCM | DEXCOM INC | Murphy Patrick Michael | VP, Legal Aff & Chf ... | Sell | D | 77.55 | 2,209 | 171,309 | 34,453 | 36.7 K to 34.5 K (-6.03 %) |
Mar 10 2017 | DXCM | DEXCOM INC | Murphy Patrick Michael | VP, Legal Aff & Chf ... | Sell | D | 77.55 | 1,611 | 124,934 | 36,662 | 38.3 K to 36.7 K (-4.21 %) |
Mar 10 2017 | DXCM | DEXCOM INC | Murphy Patrick Michael | VP, Legal Aff & Chf ... | Sell | D | 77.55 | 2,216 | 171,852 | 38,273 | 40.5 K to 38.3 K (-5.47 %) |
Mar 10 2017 | DXCM | DEXCOM INC | Murphy Patrick Michael | VP, Legal Aff & Chf ... | Grant | A | 0.00 | 11,361 | 11 | 40,489 | 29.1 K to 40.5 K (+39.00 %) |
Mar 08 2017 | DXCM | DEXCOM INC | SKYLER JAY S | Director | Option Exercise | M | 7.31 | 31,890 | 233,116 | 0 | |
Mar 08 2017 | DXCM | DEXCOM INC | SKYLER JAY S | Director | Sell | S | 78.13 | 31,890 | 2,491,572 | 17,246 | 49.1 K to 17.2 K (-64.90 %) |
Mar 08 2017 | DXCM | DEXCOM INC | SKYLER JAY S | Director | Buy | M | 7.31 | 31,890 | 233,116 | 49,136 | 17.2 K to 49.1 K (+184.91 %) |
Feb 24 2017 | DXCM | DEXCOM INC | DOUBLEDAY RICHARD | EVP, Chief Commerci ... | Sell | S | 78.42 | 3,182 | 249,530 | 12,733 | 15.9 K to 12.7 K (-19.99 %) |
Feb 24 2017 | DXCM | DEXCOM INC | ROPER JESS | SVP, CFO | Sell | S | 78.76 | 2,333 | 183,759 | 10,452 | 12.8 K to 10.5 K (-18.25 %) |
Feb 22 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Option Exercise | M | 8.79 | 10,000 | 87,900 | 23,649 | |
Feb 22 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Sell | S | 81.62 | 10,000 | 816,177 | 299,391 | 309.4 K to 299.4 K (-3.23 %) |
Feb 22 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Buy | M | 8.79 | 10,000 | 87,900 | 309,391 | 299.4 K to 309.4 K (+3.34 %) |
Feb 14 2017 | DXCM | DEXCOM INC | Balo Andrew K | EVP, Clinical and R ... | Option Exercise | M | 9.80 | 727 | 7,125 | 0 | |
Feb 14 2017 | DXCM | DEXCOM INC | Balo Andrew K | EVP, Clinical and R ... | Sell | S | 79.30 | 2,473 | 196,109 | 103,872 | 106.3 K to 103.9 K (-2.33 %) |
Feb 14 2017 | DXCM | DEXCOM INC | Balo Andrew K | EVP, Clinical and R ... | Sell | S | 79.30 | 727 | 57,651 | 106,345 | 107.1 K to 106.3 K (-0.68 %) |
Feb 14 2017 | DXCM | DEXCOM INC | Balo Andrew K | EVP, Clinical and R ... | Buy | M | 9.80 | 727 | 7,125 | 107,072 | 106.3 K to 107.1 K (+0.68 %) |
Feb 13 2017 | DXCM | DEXCOM INC | LISTER JOHN | General Manager, EM ... | Option Exercise | M | 8.85 | 3,000 | 26,550 | 13,939 | |
Feb 13 2017 | DXCM | DEXCOM INC | LISTER JOHN | General Manager, EM ... | Sell | S | 79.73 | 3,000 | 239,204 | 70,598 | 73.6 K to 70.6 K (-4.08 %) |
Feb 13 2017 | DXCM | DEXCOM INC | LISTER JOHN | General Manager, EM ... | Buy | M | 8.85 | 3,000 | 26,550 | 73,598 | 70.6 K to 73.6 K (+4.25 %) |
Feb 13 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Option Exercise | M | 9.80 | 7,000 | 68,600 | 0 | |
Feb 13 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Sell | S | 79.76 | 7,000 | 558,316 | 72,334 | 79.3 K to 72.3 K (-8.82 %) |
Feb 13 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Buy | M | 9.80 | 7,000 | 68,600 | 79,334 | 72.3 K to 79.3 K (+9.68 %) |
Feb 13 2017 | DXCM | DEXCOM INC | GREGG TERRANCE H | Executive Chairman | Sell | D | 79.35 | 1,421 | 112,756 | 439,845 | 441.3 K to 439.8 K (-0.32 %) |
Feb 03 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Option Exercise | M | 9.80 | 13,900 | 136,220 | 7,000 | |
Feb 03 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Sell | S | 80.00 | 13,900 | 1,112,000 | 72,334 | 86.2 K to 72.3 K (-16.12 %) |
Feb 03 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Buy | M | 9.80 | 13,900 | 136,220 | 86,234 | 72.3 K to 86.2 K (+19.22 %) |
Jan 25 2017 | DXCM | DEXCOM INC | DOUBLEDAY RICHARD | EVP, Chief Commerci ... | Sell | S | 79.50 | 3,182 | 252,978 | 15,915 | 19.1 K to 15.9 K (-16.66 %) |
Jan 25 2017 | DXCM | DEXCOM INC | Pacelli Steven Robert | EVP, Strategy & Cor ... | Option Exercise | M | 7.79 | 9,637 | 75,072 | 0 | |
Jan 25 2017 | DXCM | DEXCOM INC | Pacelli Steven Robert | EVP, Strategy & Cor ... | Sell | S | 79.99 | 9,637 | 770,908 | 110,409 | 120 K to 110.4 K (-8.03 %) |
Jan 25 2017 | DXCM | DEXCOM INC | Pacelli Steven Robert | EVP, Strategy & Cor ... | Buy | M | 7.79 | 9,637 | 75,072 | 120,046 | 110.4 K to 120 K (+8.73 %) |
Jan 20 2017 | DXCM | DEXCOM INC | ROPER JESS | SVP, CFO | Sell | S | 85.01 | 3,012 | 256,051 | 12,785 | 15.8 K to 12.8 K (-19.07 %) |
Jan 19 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Option Exercise | M | 8.79 | 10,000 | 87,900 | 33,649 | |
Jan 19 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Sell | S | 85.94 | 10,000 | 859,362 | 299,391 | 309.4 K to 299.4 K (-3.23 %) |
Jan 19 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Buy | M | 8.79 | 10,000 | 87,900 | 309,391 | 299.4 K to 309.4 K (+3.34 %) |
Jan 18 2017 | DXCM | DEXCOM INC | LISTER JOHN | General Manager, EM ... | Option Exercise | M | 8.85 | 15,000 | 132,750 | 16,939 | |
Jan 18 2017 | DXCM | DEXCOM INC | LISTER JOHN | General Manager, EM ... | Sell | S | 79.36 | 15,000 | 1,190,400 | 70,598 | 85.6 K to 70.6 K (-17.52 %) |
Jan 18 2017 | DXCM | DEXCOM INC | LISTER JOHN | General Manager, EM ... | Buy | M | 8.85 | 15,000 | 132,750 | 85,598 | 70.6 K to 85.6 K (+21.25 %) |
Jan 18 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Option Exercise | M | 9.80 | 7,173 | 70,295 | 20,900 | |
Jan 18 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Option Exercise | M | 9.80 | 8,927 | 87,485 | 0 | |
Jan 18 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Option Exercise | M | 7.63 | 10,000 | 76,300 | 0 |